Neratnam Diagnostic Centre Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.95 M
- Revenue Growth -8.70%
- Profit Growth -10.22%
- Ebitda 10.66%
- Net Worth 62.14%
- Total Assets 27.55%
About Neratnam Diagnostic Centre
Neratnam Diagnostic Centre Private Limited (NDCPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 November 2010 and has a history of 14 years and three months. Its registered office is in 24 Parganas, West Bengal, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.95 M.
Namita Mazumder, Partha Majumder, and Priyatosh Mazumder serve as directors at the Company.
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85190WB2010PTC154562
- Company No.
154562
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Nov 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Neratnam Diagnostic Centre?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Namita Mazumder  | Director | 10-Nov-2010 | Current |
| Partha Majumder | Director | 22-Aug-2011 | Current |
| Priyatosh Mazumder | Director | 03-Mar-2014 | Current |
Financial Performance of Neratnam Diagnostic Centre.
Neratnam Diagnostic Centre Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 8.7% decrease. The company also saw a substantial fall in profitability, with a 10.22% decrease in profit. The company's net worth Soared by an impressive increase of 62.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neratnam Diagnostic Centre?
In 2019, Neratnam Diagnostic Centre had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.95 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Mar 2017 | Others | ₹3.95 M | Open |
How Many Employees Work at Neratnam Diagnostic Centre?
Unlock and access historical data on people associated with Neratnam Diagnostic Centre, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neratnam Diagnostic Centre, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neratnam Diagnostic Centre's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
